Mark Tullman

1.5k total citations
16 papers, 401 citations indexed

About

Mark Tullman is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Mark Tullman has authored 16 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pathology and Forensic Medicine, 10 papers in Neurology and 4 papers in Rheumatology. Recurrent topics in Mark Tullman's work include Multiple Sclerosis Research Studies (11 papers), Peripheral Neuropathies and Disorders (8 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). Mark Tullman is often cited by papers focused on Multiple Sclerosis Research Studies (11 papers), Peripheral Neuropathies and Disorders (8 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). Mark Tullman collaborates with scholars based in United States, Canada and Belgium. Mark Tullman's co-authors include Fred Lublin, Dagmar Amtmann, Marcia Finlayson, Adrián L. Rabinowicz, Susan E. Bennett, Gary Cutter, George H. Kraft, Aaron E. Miller, Mitchell S.V. Elkind and Massimo Filippi and has published in prestigious journals such as Neurology, Multiple Sclerosis Journal and Expert Opinion on Drug Metabolism & Toxicology.

In The Last Decade

Mark Tullman

16 papers receiving 387 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Tullman United States	10	269	89	63	62	55	16	401
Laura Willis United States	7	305 1.1×	86 1.0×	79 1.3×	54 0.9×	52 0.9×	9	376
Wanda Castro-Borrero United States	8	227 0.8×	61 0.7×	56 0.9×	73 1.2×	48 0.9×	12	368
M.C. Edo Spain	8	262 1.0×	96 1.1×	81 1.3×	31 0.5×	63 1.1×	10	334
Lynn Stazzone United States	9	431 1.6×	152 1.7×	75 1.2×	81 1.3×	91 1.7×	10	530
Frank Hoffmann Germany	12	240 0.9×	120 1.3×	28 0.4×	74 1.2×	33 0.6×	31	450
Francesco Crescenzo Italy	12	258 1.0×	122 1.4×	52 0.8×	40 0.6×	42 0.8×	27	383
A Calò Italy	7	369 1.4×	162 1.8×	86 1.4×	72 1.2×	133 2.4×	8	557
Małgorzata Siger Poland	7	218 0.8×	79 0.9×	76 1.2×	68 1.1×	27 0.5×	22	403
M. W. Tas Netherlands	6	324 1.2×	103 1.2×	90 1.4×	69 1.1×	66 1.2×	7	391
Wiebke Stark Germany	9	266 1.0×	127 1.4×	47 0.7×	49 0.8×	70 1.3×	13	353

Countries citing papers authored by Mark Tullman

Since Specialization

Citations

This map shows the geographic impact of Mark Tullman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Tullman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Tullman more than expected).

Fields of papers citing papers by Mark Tullman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Tullman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Tullman. The network helps show where Mark Tullman may publish in the future.

Co-authorship network of co-authors of Mark Tullman

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Tullman. A scholar is included among the top collaborators of Mark Tullman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Tullman. Mark Tullman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Bar‐Or, Amit, Ángel Chinea, Barry Hendin, et al.. (2023). Humoral immune response to COVID-19 mRNA vaccines in patients with relapsing multiple sclerosis treated with ofatumumab. Multiple Sclerosis and Related Disorders. 79. 104967–104967. 3 indexed citations

Tullman, Mark, et al.. (2021). Evaluation Of Infusion Reactions And Infusion Times In The N-Momentum Study Of Inebilizumab For NMOSD (1941). Neurology. 96(15_supplement). 2 indexed citations

Tullman, Mark, et al.. (2021). Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder. Neurodegenerative Disease Management. 11(5). 341–352. 8 indexed citations

Tullman, Mark, Emmanuel Chartier‐Kastler, V. Keppenne, et al.. (2018). Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS. Neurology. 91(7). e657–e665. 13 indexed citations

Tullman, Mark, et al.. (2015). A Pilot Study of Dalfampridine for Improving Upper Extremity Function in Multiple Sclerosis Patients (P1.124). Neurology. 84(14_supplement). 1 indexed citations

Kraft, George H., Dagmar Amtmann, Susan E. Bennett, et al.. (2014). Assessment of Upper Extremity Function in Multiple Sclerosis: Review and Opinion. Postgraduate Medicine. 126(5). 102–108. 39 indexed citations

Coyle, Patricia K., Bruce A. Cohen, Thomas Leist, et al.. (2014). Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes. BMC Neurology. 14(1). 49–49. 10 indexed citations

Tullman, Mark. (2013). A review of current and emerging therapeutic strategies in multiple sclerosis.. PubMed. 19(2 Suppl). S21–7. 37 indexed citations

Tullman, Mark. (2013). Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis.. PubMed. 19(2 Suppl). S15–20. 200 indexed citations

10.

Grinspan, Zachary M., Joshua Z. Willey, Mark Tullman, & Mitchell S.V. Elkind. (2009). Clinical Reasoning: A 28-year-old pregnant woman with encephalopathy. Neurology. 73(15). e74–9. 9 indexed citations

11.

Perumal, Jai, Massimo Filippi, Corey C. Ford, et al.. (2006). Glatiramer acetate therapy for multiple sclerosis: a review. Expert Opinion on Drug Metabolism & Toxicology. 2(6). 1019–1029. 17 indexed citations

12.

Tullman, Mark & Fred Lublin. (2005). Combination therapy in multiple sclerosis. Current Neurology and Neuroscience Reports. 5(3). 245–248. 16 indexed citations

13.

Tullman, Mark. (2004). SYMPTOMATIC THERAPY IN MULTIPLE SCLEROSIS. CONTINUUM Lifelong Learning in Neurology. 10(6). 142–172. 7 indexed citations

14.

Tullman, Mark, et al.. (2004). Clinical characteristics of progressive relapsing multiple sclerosis. Multiple Sclerosis Journal. 10(4). 451–454. 21 indexed citations

15.

Tullman, Mark, Bradley N. Delman, Fred Lublin, & Jesse Weinberger. (2003). Magnetic Resonance Imaging of Meningoradiculomyelitis in Early Disseminated Lyme Disease. Journal of Neuroimaging. 13(3). 264–268. 9 indexed citations

16.

Tullman, Mark, Fred Lublin, & Aaron E. Miller. (2002). Immunotherapy of multiple sclerosis--current practice and future directions.. PubMed. 39(2). 273–85. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact